Oscotec Inc. (039200.KQ) KOE

40,000.00

+50(+0.13%)

Updated at October 20 09:29AM

Currency In KRW

Oscotec Inc.

Address

A Building, Korea Bio Park

Seongnam-si, 13488

Korea, Republic of

Phone

82 3 1628 7666

Sector

Healthcare

Industry

Drug Manufacturers - General

Employees

50

First IPO Date

January 17, 2007

Key Executives

NameTitlePayYear Born
Mr. Jeung-Keun KimChief Executive Officer01960
Sung-Hee SonExecutive Officer0N/A
Su-Sung LeeExecutive Officer0N/A
Sung-Ho ParkExecutive Officer01968
So-Jin AhnExecutive Officer0N/A
Ju-Won KimExecutive Officer0N/A
Jae-Sang LeeExecutive Officer0N/A
Se-Nyun KimExecutive Officer0N/A
Seung-Chul LeeExecutive Officer01963
Hirose DakashiExecutive Officer0N/A

Description

Oscotec Inc. operates as a clinical stage drug discovery and development company. It develops SYK inhibitor that is in Phase IIa clinical trial to treat rheumatoid arthritis and immune thrombocytopenia; FLT3 inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; and EGFR double mutation inhibitor to treat non-small cell lung cancer, as well as Anti-Tau antibody, which is in preclinical Phase for the treatment of Alzheimer's disease. The company also offers dental health products, such as bone graft comprising InduCera, BioCera-F, and SynCeraII; and membrane consisting of LysoGide and CollaGuide. In addition, it provides functional ingredients comprises OPB for osteoporosis; AIF for arthritis; SGA that enhance bone growth; and PRF-K for perio diseases. The company was formerly known as Oscotec Co., Ltd and changed its name to Oscotec Inc. in June 1999. Oscotec Inc. was founded in 1988 and is based in Seongnam, South Korea.